Literature DB >> 9504519

CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study.

D Kaufmann, G Pantaleo, P Sudre, A Telenti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9504519     DOI： 10.1016/s0140-6736(98)24010-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  39 in total

Review 1.  Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.

Authors:  G R Kaufmann; J Zaunders; D A Cooper
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

2.  Immune Reconstitution and the Consequences for Opportunistic Infection Treatment and Prevention.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

3.  Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment.

Authors:  L Sarmati; G d'Ettorre; E Nicastri; L Ercoli; I Uccella; P Massetti; S G Parisi; V Vullo; M Andreoni
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

4.  Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients.

Authors:  P M Roger; J P Breittmayer; C Arlotto; P Pugliese; C Pradier; G Bernard-Pomier; P Dellamonica; A Bernard
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

5.  Novel antiretroviral agents in HIV therapy.

Authors:  Caitlin Reed; Eric S Daar
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.725

Review 6.  The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications.

Authors:  C Fraser; N M Ferguson; F de Wolf; R M Anderson
Journal:  Proc Biol Sci       Date:  2001-10-22       Impact factor: 5.349

7.  Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.

Authors:  Matthew Bidwell Goetz; Monique R Ferguson; Xueliang Han; Greg McMillan; Marty St Clair; Keith A Pappa; Daniel R McClernon; William A O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-15       Impact factor: 3.731

Review 8.  The role of protease inhibitor therapy in children with HIV infection.

Authors:  Patrick J Gavin; Ram Yogev
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

9.  Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation.

Authors:  Ozlem Equils; Alan Shapiro; Zeynep Madak; Chunren Liu; Daning Lu
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.

Authors:  Emanuele Nicastri; Loredana Sarmati; Gabriella d'Ettorre; Saverio G Parisi; Lucia Palmisano; Clementina Galluzzo; Marco Montano; Ilaria Uccella; Roberta Amici; Francesca Gatti; Vincenzo Vullo; Ercole Concia; Stefano Vella; Massimo Andreoni
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.